Clarification22 Jul 2026, 01:41 pm
Transgene Biotek: Statement of Deviation/Variation Not Applicable for Q1 FY27
AI Summary
Transgene Biotek Ltd has stated that the Statement of Deviation or Variation for proceeds of public issue, rights issue, preferential issue, or QIP is not applicable for the quarter ended June 30, 2026. This is because the company had no such issues during the reporting period. The company also noted that it was unable to file the statement in XBRL mode as the form does not permit NIL entries.
Key Highlights
- No public, rights, or preferential issues occurred in the quarter.
- Statement of Deviation/Variation is therefore not applicable.
- XBRL filing issue noted for NIL entries.
- Company provides clarification on regulatory filing status.
Price Impact
More from TRABI